Nutrien (NYSE:NTR – Get Free Report) had its price objective raised by investment analysts at Mizuho from $52.00 to $55.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Mizuho’s price objective indicates a potential upside of 3.58% from the company’s current price.
Several other equities research analysts have also recently commented on NTR. Barclays reaffirmed an “equal weight” rating and issued a $56.00 price objective (up from $55.00) on shares of Nutrien in a research report on Tuesday, January 21st. JPMorgan Chase & Co. raised shares of Nutrien from an “underweight” rating to a “neutral” rating and boosted their price target for the stock from $40.00 to $50.00 in a research report on Monday, January 13th. Oppenheimer began coverage on shares of Nutrien in a research note on Thursday, December 12th. They set an “outperform” rating and a $60.00 price objective for the company. CIBC restated an “outperformer” rating and set a $55.00 price objective (down from $60.00) on shares of Nutrien in a research note on Tuesday, December 10th. Finally, Piper Sandler increased their price objective on shares of Nutrien from $58.00 to $63.00 and gave the stock an “overweight” rating in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $59.22.
Get Our Latest Research Report on Nutrien
Nutrien Price Performance
Nutrien (NYSE:NTR – Get Free Report) last released its earnings results on Wednesday, February 19th. The company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.09). Nutrien had a return on equity of 6.99% and a net margin of 2.79%. The business had revenue of $5.08 billion for the quarter, compared to analyst estimates of $5.09 billion. As a group, research analysts predict that Nutrien will post 3.49 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of NTR. Goodman Financial Corp increased its stake in shares of Nutrien by 4.6% in the third quarter. Goodman Financial Corp now owns 253,860 shares of the company’s stock worth $12,201,000 after buying an additional 11,058 shares during the period. CORDA Investment Management LLC. grew its stake in shares of Nutrien by 7.0% in the third quarter. CORDA Investment Management LLC. now owns 494,745 shares of the company’s stock worth $23,777,000 after acquiring an additional 32,541 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Nutrien by 10.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,742,351 shares of the company’s stock valued at $83,812,000 after purchasing an additional 157,932 shares during the last quarter. Stephens Inc. AR boosted its stake in shares of Nutrien by 335.0% in the 3rd quarter. Stephens Inc. AR now owns 70,301 shares of the company’s stock worth $3,379,000 after buying an additional 54,138 shares during the last quarter. Finally, Covea Finance increased its position in shares of Nutrien by 21.9% during the 4th quarter. Covea Finance now owns 55,600 shares of the company’s stock valued at $2,485,000 after purchasing an additional 10,000 shares during the last quarter. 63.10% of the stock is currently owned by hedge funds and other institutional investors.
Nutrien Company Profile
Nutrien Ltd. provides crop inputs and services. The company operates through four segments: Retail, Potash, Nitrogen, and Phosphate. The Retail segment distributes crop nutrients, crop protection products, seeds, and merchandise products. The Potash segment provides granular and standard potash products.
Read More
- Five stocks we like better than Nutrien
- What is the S&P/TSX Index?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
- Using the MarketBeat Dividend Tax Calculator
- Should You Hold NVIDIA Stock for the Long Haul or Trade It?
- Find and Profitably Trade Stocks at 52-Week Lows
- Humana Gains Despite Medicare Advantage Losses—What’s the Catch?
Receive News & Ratings for Nutrien Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutrien and related companies with MarketBeat.com's FREE daily email newsletter.